In 2010 the global acute myeloid leukaemia (AML) therapeutics market was worth a total value of $204 million. Over the next five years the industry is expected to increase at a compound annual growth rate (CAGR) of 17.1%, to reach a market value of $617 million by 2017.
Growth within the market looks set to be driven by the entry of premium priced products along with the aging population.
The risk of developing AML is closely associated with age. Approximately 90% of AML cases are diagnosed once a patient reached middle age, with the incidence rate of AML being severely high in men and women over 50 years of age.
The median age of an AML patient is 67 years, with patients aged 60 and over growing faster than all other age groups. Between 2009 and 2017 this amount is expected to increase from 950 million to 1.2 billion. The yearly incidence of AML in the US is 17.6/100,000 for people 65 years of age or older, compared to 1.8/100,000 for people <65 year.
AML is expected to be more prominent in the developed world due to genetic and environmental factors, with radiation exposure being the primary cause of all types of AML.
Global incidence of AML was measured at 49,539 in 2008 within the developing countries. A total of 62,226 new cases were recorded in 2010, with 95,211 and 129,837 as the predicted new cases for 2015 and 2020.
The US dominates the AML drug market in North America with a 90.19% share; where as Germany dominates the market in Europe with a share of 35.04%.
Cephalon Inc, Celgene Corporation, Eisai Co. Ltd, and Sunesis Pharmaceuticals currently rule the AML drugs market; whereas Ambit Bioscience is expected to capture major share of the market by 2020.
For more information on the acute myeloid leukaemia therapeutics market, see the latest research: Acute Myeloid Leukaemia Therapeutics Market Report
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.